Four months after securing $125 million in funding, SpringWorks Therapeutics is eying another $115 million from a potential initial public offering.

Pfizer launched a six-person biotech startup, SpringWorks Therapeutics, with a $103 million Series A financing. Joining Pfizer in funding the company was Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed and LifeArc, formerly known as MRC Technology.